Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)
Sandostatin, Sandostatin LAR®
Immune system and Malignant Disease
Octreotide are recommended for the non-acute treatment of recurrent gastrointestinal bleeding disorders. Initiation and continued supply of Octreotide is the responsibility of hospital or specialist services.
Octreotide are not licensed for this indication and there is not a large body of evidence to support this unlicensed use.
Treatment should only be continued if an adequate response is achieved (e.g. a 50% reduction in the need for transfusion or parenteral iron).
Reason for decision: